Cytomegalovirus

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Among agents that cause congenital or perinatal infection, cytomegalovirus (CMV) is the most commonly encountered pathogen and is responsible for substantial sequelae in infants. Globally the burden of congenital CMV (cCMV) is underestimated, since surveillance programs are not present in many parts of the world, but in the developed world it is estimated that the birth prevalence is 0.64%, and somewhere between 10% and 15% of infected infants will have long-term neurodevelopmental sequelae, most commonly sensorineural hearing loss. Given the morbidity associated with cCMV infection, development of a safe and effective preconception vaccine is a major public health priority. However, re-infections, with resultant disabling congenital transmission, occur in women with preconception immunity, greatly complicating vaccine design. This chapter summarizes the current state of CMV vaccine development, with an emphasis both on postulated correlates of protective maternal immunity and candidate vaccines moving forward in clinical trials.

Original languageEnglish (US)
Title of host publicationMaternal Immunization
PublisherElsevier
Pages253-288
Number of pages36
ISBN (Electronic)9780128145821
ISBN (Print)9780128145838
DOIs
StatePublished - Jan 1 2019

Keywords

  • CMV vaccines
  • Congenital CMV infection
  • Cytomegalovirus
  • Herpesviruses
  • Sensorineural hearing loss
  • TORCH infections
  • Viral envelope glycoproteins

Fingerprint Dive into the research topics of 'Cytomegalovirus'. Together they form a unique fingerprint.

Cite this